The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
Open accessAbstract
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an incidence of over 20 000 cases per year in the United States alone. Large chromosomal translocations as well as mutations in the genes involved in hematopoietic proliferation and differentiation result in the accumulation of poorly differentiated myeloid cells. AML is a highly heterogeneous disease; although cases can be stratified into favorable, intermediate and adverse-risk groups based on their cytogenetic profile, prognosis within these categories varies widely. The identification of recurrent genetic mutations, such as FLT3-ITD, NMP1 and CEBPA, has helped refine individual prognosis and guide management. Despite advances in supportive care, the backbone of therapy remains a combination of cytarabine- and anthracycline-based regimens with allogeneic stem cell transplantation for eligible candidates. Elderly patients are often unable to tolerate such regimens, and carry a particularly poor prognosis. Here, we review the major recent advances in the treatment of AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,169
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Fernandez, H. F., Sun, Z., Yao, X., Litzow, M. R., Luger, S. M., Paietta, E. M., Racevskis, J., Dewald, G. W., Ketterling, R. P., Bennett, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904544 · Cited by 919
Koreth, J., Schlenk, R., Kopecky, K. J., Honda, S., Sierra, J., Djulbegovic, B. J., Wadleigh, M., DeAngelo, D. J., Stone, R. M., Sakamaki, H., et al. (2009) · JAMA · doi:10.1001/jama.2009.813 · Cited by 886
Fröhling, S., Schlenk, R. F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2002) · Blood · doi:10.1182/blood-2002-05-1440 · Cited by 871
Döhner, K., Schlenk, R. F., Habdank, M., Scholl, C., Rücker, F. G., Corbacioglu, A., Bullinger, L., Fröhling, S., Döhner, H., & for the AML Study Group (AMLSG) (2005) · Blood · doi:10.1182/blood-2005-05-2164 · Cited by 849
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Gale, R. E., Green, C., Allen, C., Mead, A. J., Burnett, A. K., Hills, R. K., & Linch, D. C. (2008) · Blood · doi:10.1182/blood-2007-08-109090 · Cited by 745
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Paschka, P., Marcucci, G., Ruppert, A. S., Mrózek, K., Chen, H., Kittles, R. A., Vukosavljevic, T., Perrotti, D., Vardiman, J. W., Carroll, A. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9500 · Cited by 663
Stone, R. M., DeAngelo, D. J., Klimek, V., Galinsky, I., Estey, E., Nimer, S. D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., et al. (2005) · Blood · doi:10.1182/blood-2004-03-0891 · Cited by 657
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia‐Manero, G., Wierda, W., Pierce, S., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 610
Fischer, T., Stone, R. M., DeAngelo, D. J., Galinsky, I., Estey, E., Lanza, C., Fox, E., Ehninger, G., Feldman, E. J., Schiller, G. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9678 · Cited by 504
Cornelissen, J. J., van Putten, W. L. J., Verdonck, L. F., Theobald, M., Jacky, E., Daenen, S. M. G., van Marwijk Kooy, M., Wijermans, P., Schouten, H., Huijgens, P. C., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025627 · Cited by 471
Kenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V, Morrissette, J. J. D., Scholler, J., Song, D., Porter, D. L., Carroll, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 426
Yin, J. A. L., O'Brien, M. A., Hills, R. K., Daly, S. B., Wheatley, K., & Burnett, A. K. (2012) · Blood · doi:10.1182/blood-2012-06-435669 · Cited by 425
Weick, J., Kopecky, K., Appelbaum, F., Head, D., Kingsbury, L., Balcerzak, S., Bickers, J., Hynes, H., Welborn, J., Simon, Sr., et al. (1996) · Blood · doi:10.1182/blood.v88.8.2841.bloodjournal8882841 · Cited by 411
Cytarabine Dose for Acute Myeloid Leukemia
Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Biemond, B. J., Gratwohl, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010222 · Cited by 407
Mrózek, K., Marcucci, G., Nicolet, D., Maharry, K. S., Becker, H., Whitman, S. P., Metzeler, K. H., Schwind, S., Wu, Y.-Z., Kohlschmidt, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4738 · Cited by 406
Schlenk, R. F., Kayser, S., Bullinger, L., Kobbe, G., Casper, J., Ringhoffer, M., Held, G., Brossart, P., Lübbert, M., Salih, H. R., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578070 · Cited by 404
Röllig, C., Serve, H., Hüttmann, A., Noppeney, R., Müller-Tidow, C., Krug, U., Baldus, C. D., Brandts, C. H., Kunzmann, V., Einsele, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00362-9 · Cited by 401
Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., Coutre, S., Erba, H., Stuart, R. K., Baccarani, M., Cripe, L. D., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301796 · Cited by 398
Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M., Solbu, G., & Suciu, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1268 · Cited by 384
Yamamoto, J. F., & Goodman, M. T. (2008) · Cancer Causes & Control · doi:10.1007/s10552-007-9097-2 · Cited by 383
Ravandi, F., Alattar, M. L., Grunwald, M. R., Rudek, M. A., Rajkhowa, T., Richie, M. A., Pierce, S., Daver, N., Garcia-Manero, G., Faderl, S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-480228 · Cited by 381
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0060 · Cited by 362
Cortes, J. E., Kantarjian, H., Foran, J. M., Ghirdaladze, D., Zodelava, M., Borthakur, G., Gammon, G., Trone, D., Armstrong, R. C., James, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.8783 · Cited by 361
Ravandi, F., Cortes, J. E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M. Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4888 · Cited by 356
Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
Zhang, W., Konopleva, M., Shi, Y.-X., McQueen, T., Harris, D., Ling, X., Estrov, Z., Quintás-Cardama, A., Small, D., Cortes, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm328 · Cited by 338
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
DiNardo, C. D., Ravandi, F., Agresta, S., Konopleva, M., Takahashi, K., Kadia, T., Routbort, M., Patel, K. P., Brandt, M., Pierce, S., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24072 · Cited by 325
Serve, H., Krug, U., Wagner, R., Sauerland, M. C., Heinecke, A., Brunnberg, U., Schaich, M., Ottmann, O., Duyster, J., Wandt, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4990 · Cited by 313
Man, C. H., Fung, T. K., Ho, C., Han, H. H. C., Chow, H. C. H., Ma, A. C. H., Choi, W. W. L., Lok, S., Cheung, A. M. S., Eaves, C., et al. (2012) · Blood · doi:10.1182/blood-2011-06-363960 · Cited by 279
Hulegårdh, E., Nilsson, C., Lazarevic, V., Garelius, H., Antunovic, P., Rangert Derolf, Å., Möllgård, L., Uggla, B., Wennström, L., Wahlin, A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23908 · Cited by 269
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Sato, T., Yang, X., Knapper, S., White, P., Smith, B. D., Galkin, S., Small, D., Burnett, A., & Levis, M. (2011) · Blood · doi:10.1182/blood-2010-01-266742 · Cited by 261
Redell, M. S., Ruiz, M. J., Alonzo, T. A., Gerbing, R. B., & Tweardy, D. J. (2011) · Blood · doi:10.1182/blood-2010-04-280123 · Cited by 257
Chen, X., Xie, H., Wood, B. L., Walter, R. B., Pagel, J. M., Becker, P. S., Sandhu, V. K., Abkowitz, J. L., Appelbaum, F. R., & Estey, E. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3518 · Cited by 257
Buccisano, F., Maurillo, L., Del Principe, M. I., Del Poeta, G., Sconocchia, G., Lo-Coco, F., Arcese, W., Amadori, S., & Venditti, A. (2012) · Blood · doi:10.1182/blood-2011-08-363291 · Cited by 256
A novel hierarchical prognostic model of AML solely based on molecular mutations
Grossmann, V., Schnittger, S., Kohlmann, A., Eder, C., Roller, A., Dicker, F., Schmid, C., Wendtner, C.-M., Staib, P., Serve, H., et al. (2012) · Blood · doi:10.1182/blood-2012-03-419622 · Cited by 252
Kihara, R., Nagata, Y., Kiyoi, H., Kato, T., Yamamoto, E., Suzuki, K., Chen, F., Asou, N., Ohtake, S., Miyawaki, S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.55 · Cited by 237
Chen, Y.-B., Li, S., Lane, A. A., Connolly, C., Del Rio, C., Valles, B., Curtis, M., Ballen, K., Cutler, C., Dey, B. R., et al. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.09.007 · Cited by 236
Ross, J. F., Wang, H., Behm, F. G., Mathew, P., Wu, M., Booth, R., & Ratnam, M. (1999) · Cancer · Cited by 225
Metzelder, S. K., Schroeder, T., Finck, A., Scholl, S., Fey, M., Götze, K., Linn, Y. C., Kröger, M., Reiter, A., Salih, H. R., et al. (2012) · Leukemia · doi:10.1038/leu.2012.105 · Cited by 224
Crenolanib is a selective type I pan-FLT3 inhibitor
Smith, C. C., Lasater, E. A., Lin, K. C., Wang, Q., McCreery, M. Q., Stewart, W. K., Damon, L. E., Perl, A. E., Jeschke, G. R., Sugita, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320661111 · Cited by 211
Survival and cure of acute myeloid leukaemia in England, 1971‐2006: a population–based study
Shah, A., Andersson, T. M. ‐., Rachet, B., Björkholm, M., & Lambert, P. C. (2013) · British Journal of Haematology · doi:10.1111/bjh.12425 · Cited by 206
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
Borthakur, G., Kantarjian, H., Ravandi, F., Zhang, W., Konopleva, M., Wright, J. J., Faderl, S., Verstovsek, S., Mathews, S., Andreeff, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.030452 · Cited by 202
Schuringa, J.-J., Wierenga, A. T. J., Kruijer, W., & Vellenga, E. (2000) · Blood · doi:10.1182/blood.v95.12.3765 · Cited by 200
Faderl, S., Ravandi, F., Huang, X., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Borthakur, G., Verstovsek, S., Thomas, D. A., Kwari, M., et al. (2008) · Blood · doi:10.1182/blood-2007-11-124602 · Cited by 200
Kantarjian, H. M., Erba, H. P., Claxton, D., Arellano, M., Lyons, R. M., Kovascovics, T., Gabrilove, J., Craig, M., Douer, D., Maris, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3130 · Cited by 192
Spiekermann, K., Bagrintseva, K., Schwab, R., Schmieja, K., & Hiddemann, W. (2003) · PubMed · Cited by 184
Jabbour, E., Kantarjian, H., O’Brien, S., Cortes, J., Giles, F., Faderl, S., Garcia-Manero, G., Wierda, W., Pierce, S., Shan, J., et al. (2005) · Blood · doi:10.1182/blood.v106.11.1846.1846 · Cited by 183
Lynn, R. C., Poussin, M., Kalota, A., Feng, Y., Low, P. S., Dimitrov, D. S., & Powell, D. J. (2015) · Blood · doi:10.1182/blood-2014-11-612721 · Cited by 182
Faderl, S., Wetzler, M., Rizzieri, D., Schiller, G., Jagasia, M., Stuart, R., Ganguly, S., Avigan, D., Craig, M., Collins, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9743 · Cited by 176
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2012-07-444851 · Cited by 165
Zhou, J., Bi, C., Janakakumara, J. V., Liu, S.-C., Chng, W.-J., Tay, K.-G., Poon, L.-F., Xie, Z., Palaniyandi, S., Yu, H., et al. (2009) · Blood · doi:10.1182/blood-2008-05-156422 · Cited by 162
Stone, R. M., Mandrekar, S., Sanford, B. L., Geyer, S., Bloomfield, C. D., Dohner, K., Thiede, C., Marcucci, G., Lo-Coco, F., Klisovic, R. B., et al. (2015) · Blood · doi:10.1182/blood.v126.23.6.6 · Cited by 159
Strati, P., Kantarjian, H. M., Ravandi, F., Nazha, A., Borthakur, G. M., Daver, N. G., Kadia, T. M., Estrov, Z. E., Garcia‐Manero, G., Konopleva, M. Y., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23924 · Cited by 156
Meyers, J., Yu, Y., Kaye, J. A., & Davis, K. L. (2013) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0032-2 · Cited by 152
Steensma, D. P., McClure, R. F., Karp, J. E., Tefferi, A., Lasho, T. L., Powell, H. L., Dewald, G., & Kaufmann, S. H. (2006) · Leukemia · doi:10.1038/sj.leu.2404206 · Cited by 148
Büchner, T., Schlenk, R. F., Schaich, M. A., Döhner, K., Krahl, R., Krauter, J., Heil, G., Krug, U. O., Sauerland, M. C., Heinecke, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2907 · Cited by 136
Burnett, A. K., Russell, N. H., Hunter, A., Milligan, D. W., Knapper, S., Wheatley, K., Yin, J., McMullin, M. F., Ali, S., Bowen, D., et al. (2013) · Blood · doi:10.1182/blood-2013-04-496596 · Cited by 132
Current findings for recurring mutations in acute myeloid leukemia
Takahashi, S. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-36 · Cited by 132
Therapy‐related myeloid neoplasms: pathobiology and clinical characteristics
Sill, H., Olipitz, W., Zebisch, A., Schulz, E., & Wölfler, A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01100.x · Cited by 128
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Oh, D., Lee, S., Han, S., Kim, M., Kim, T.-M., Kim, T., Heo, D. S., Yuasa, M., Yanagihara, Y., & Bang, Y. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.249 · Cited by 128
Cook, A., Li, L., Ho, Y., Lin, A., Li, L., Stein, A. S., Forman, S. J., Perrotti, D., Jove, R., & Bhatia, R. (2014) · Blood · doi:10.1182/blood-2013-05-505735 · Cited by 116
Port, M., Böttcher, M., Thol, F. R., Ganser, A., Schlenk, R. F., Wasem, J., Neumann, A., & Pouryamout, L. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2072-6 · Cited by 108
Hayakawa, F., Sugimoto, K., Harada, Y., Hashimoto, N., Ohi, N., Kurahashi, S., & Naoe, T. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.63 · Cited by 108
Stelljes, M., Krug, U. O., Beelen, D. W., Braess, J., Sauerland, M. C., Heinecke, A., Ligges, S., Sauer, T., Tschanter, P., Thoennissen, G. B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5768 · Cited by 106
Shivarov, V. S., Gueorguieva, R. V., Stoimenov, A., & Tiu, R. V. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.07.032 · Cited by 95
Antar, A. I., Kharfan‐Dabaja, M. A., Mahfouz, R. A., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.12.005 · Cited by 90
Wang, H., Zheng, X., Behm, F. G., & Ratnam, M. (2000) · Blood · doi:10.1182/blood.v96.10.3529 · Cited by 88
Crump, M., Hedley, D. W., Kamel‐Reid, S., Leber, B. F., Wells, R. W., Brandwein, J. M., Buckstein, R. J., Kassis, J., Minden, M. D., Matthews, J., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903585286 · Cited by 84
A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients
Cooper, B., Kindwall‐Keller, T. L., Craig, M., Creger, R. J., Hamadani, M., Tse, W. W., & Lazarus, H. M. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.017 · Cited by 79
Röllig, C., Bornhäuser, M., Krämer, M., Thiede, C., Ho, A. D., Krämer, A., Schäfer‐Eckart, K., Wandt, H., Hänel, M., Einsele, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.4973 · Cited by 79
Swaminathan, M., Kantarjian, H. M., Daver, N. G., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.723.723 · Cited by 73
Targeting FLT3 to treat leukemia
Koenig, H., & Levis, M. J. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.960843 · Cited by 72
Li, X., Xu, S., Tan, Y., & Chen, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010432.pub2 · Cited by 50
Hoyos, M., Nomdedeu, J. F., Esteve, J., Duarte, R. F., Ribera, J., Llorente, A., Escoda, L., Bueno, J., Tormo, M., Gallardo, D., et al. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12130 · Cited by 48
Yamada, O., & Kawauchi, K. (2013) · JAK-STAT · doi:10.4161/jkst.25256 · Cited by 43
Li, H., Deng, D., Huang, Y., Ye, F., Huang, L., Xiao, Q., Zhang, B., Ye, B., Lai, Y., Mo, Z., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12450 · Cited by 43
Cagnetta, A., Adamia, S., Acharya, C., Patrone, F., Miglino, M., Nencioni, A., Gobbi, M., & Cea, M. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.006 · Cited by 42
Schetelig, J., Schaich, M. A., Schäfer-Eckart, K., Hänel, M., Aulitzky, W. E., Einsele, H., Schmitz, N., Rösler, W., Stelljes, M., Baldus, C. D., et al. (2014) · Leukemia · doi:10.1038/leu.2014.335 · Cited by 40
Middeke, J. M., Herbst, R., Parmentier, S. B., Bug, G., Hänel, M., Stuhler, G., Schäfer-Eckart, K., Rösler, W., Klein, S., Bethge, W. A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.226 · Cited by 36
Park, S. H., Lee, H., Kim, I., Kang, J.-E., Lee, E. Y., Kim, H., Kim, Y., Won, J.-H., Bang, S., Kim, H., et al. (2015) · Annals of Laboratory Medicine · doi:10.3343/alm.2015.35.3.288 · Cited by 29
Ghoshal, S., Baumann, H., & Wetzler, M. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.11.035 · Cited by 28
Al‐Kali, A., Cortes, J. E., Faderl, S. H., Jones, D. M., Abril, C., Pierce, S. A., Brandt, M., Kantarjian, H. M., & Ravandi, F. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.06.007 · Cited by 25
Pollyea, D. A., de Botton, S., Fathi, A. T., Stein, E. M., Tallman, M. S., Agresta, S., Bowden, C. J., Fan, B., Prah, M. A., Yang, H., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70722-1 · Cited by 22
Li, D., Wang, L., Zhu, H., Dou, L., Liu, D., Fu, L. N., Ma, C., Ma, X.-B., Yao, Y., Zhou, L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132620 · Cited by 19
Abstract 3116: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model
Ellwood-Yen, K., Wang, F., Travins, J. M., Chen, Y., Yang, H. Q., Straley, K., Choe, S. E., Dorsch, M., Agresta, S., Schenkein, D. P., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-3116 · Cited by 6
Krueger, M., Minus, M. B., Liu, W., Long, X., Stevens, A. M., Kolosov, M. I., Sison, E. A. R., Tweardy, D. J., Ball, Z. T., & Redell, M. S. (2015) · Blood · doi:10.1182/blood.v126.23.569.569 · Cited by 6
Cited by
Du, J., Wang, T., Li, Y., Zhou, Y., Wang, X., Yu, X., Ren, X., An, Y., Wu, Y., Sun, W., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.12.011 · Cited by 487
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Nepstad, I., Hatfield, K. J., Grønningsæter, I. S., & Reikvam, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082907 · Cited by 348
Sequencing thousands of single-cell genomes with combinatorial indexing
Vitak, S. A., Torkenczy, K. A., Rosenkrantz, J. L., Fields, A. J., Christiansen, L., Wong, M. H., Carbone, L., Steemers, F. J., & Adey, A. (2017) · Nature Methods · doi:10.1038/nmeth.4154 · Cited by 294
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Metadata
- Authors
- De Kouchkovsky, I., & Abdul-Hay, M.
- Venue
- Blood Cancer Journal
- Published
- 2016-07-01
- Volume
- 6
- Issue
- 7
- Pages
- e441-e441
- ISSN
- 2044-5385 (ISSN-L)
- OpenAlex
- W2461928138
- Cited by
- 1,317
- References
- 99
- FWCI
- 59.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.